nce," he continued. "That study showed the ability of exisulind (Aptosyn™) to significantly inhibit the rise in average PSA levels in treated patients compared to those on a placebo." Dr. Pamukcu noted that detailed results of the one-year prostate cancer trial would be presented on Monday May 1 at the annual meeting of the American Urological Association (AUA) in Atlanta.

Study Details

The reported research examined the ability of exisulind (Aptosyn™), CP461, CP248 and sulindac sulfide to inhibit growth and induce apoptosis in prostate cancer cell lines, irrespective of bcl-2 over-expression, androgen-dependence, or cyclooxygenase (COX) expression. The researchers showed that with doses that induced apoptosis, exisulind (Aptosyn™), CP248, and CP461 reduced cellular PSA expression and decreased the secretion of PSA from androgen-dependent LNCaP cells. At the same time, PSA levels of LNCaP cells treated with aspirin remained elevated. In addition, cells treated with exisulind (Aptosyn™) showed a decreased activity and expression of the androgen receptor.

Exisulind (Aptosyn™) is the first product candidate from a novel class of compounds under development by Cell Pathways, called selective apoptotic anti-neoplastic drugs (SAANDs). SAANDs inhibit cyclic GMP phosphodiesterase and selectively induce apoptosis (programmed cell death) in abnormally growing precancerous and cancerous cells. Because SAANDs do not induce apoptosis in normal cells, they do not produce the serious side effects normally associated with traditional chemotherapeutic agents. They also do not inhibit cyclooxygenase (COX I or COX II) and have not exhibited the gastric and renal toxicities reported to be associated with non-steroidal anti-inflammatory drugs (NSAIDs), including the COX II specific inhibitors. A New Drug Application for exisulind (Aptosyn™) as a treatment for patients with familial adenomatous polyposis, a precancerous condition tha
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000

Page: 1 2 3
Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door